SLDB
Solid Biosciences Inc

6,103
Mkt Cap
$444.87M
Volume
1.24M
52W High
$7.37
52W Low
$2.41
PE Ratio
-2.31
SLDB Fundamentals
Price
$5.75
Prev Close
$5.71
Open
$5.67
50D MA
$5.33
Beta
1.75
Avg. Volume
1.29M
EPS (Annual)
-$3.06
P/B
2.05
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB
Bollard Group LLC bought a new position in shares of Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Geode Capital Management LLC Purchases 979,294 Shares of Solid Biosciences Inc. $SLDB
Geode Capital Management LLC raised its position in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 184.5% in the second quarter, according to its most recent disclosure with the SEC. The firm...
MarketBeat·4d ago
News Placeholder
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 2,701 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average...
MarketBeat·5d ago
News Placeholder
Jessie Hanrahan Sells 4,483 Shares of Solid Biosciences (NASDAQ:SLDB) Stock
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) insider Jessie Hanrahan sold 4,483 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Solid Biosciences (NASDAQ:SLDB) CEO Sells 10,808 Shares
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 10,808 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells 4,932 Shares of Stock
Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) COO David Howton sold 4,932 shares of the company's stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...
MarketBeat·5d ago
News Placeholder
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst
Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.read more...
Benzinga·6d ago
News Placeholder
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat...
MarketBeat·22d ago
News Placeholder
Solid Biosciences (NASDAQ:SLDB) Price Target Cut to $14.00 by Analysts at Citigroup
Citigroup dropped their price objective on shares of Solid Biosciences from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
JPMorgan Chase & Co. Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price
JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $13.00 to $11.00 and set an "overweight" rating for the company in a report on Wednesday...
MarketBeat·1mo ago

Latest SLDB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.